Short-term versus long-term safety of dual antiplatelet therapy (DAPT) with drug-eluting stents is dominating much of the conversation at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.
Results of two separate studies, EVOLVE Short DAPT and Model U-SES, that looked at the safety of three-month DAPT in subjects at high risk for bleeding after stent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?